PT - JOURNAL ARTICLE AU - Cele, Sandile AU - Gazy, Inbal AU - Jackson, Laurelle AU - Hwa, Shi-Hsia AU - Tegally, Houriiyah AU - Lustig, Gila AU - Giandhari, Jennifer AU - Pillay, Sureshnee AU - Wilkinson, Eduan AU - Naidoo, Yeshnee AU - Karim, Farina AU - Ganga, Yashica AU - Khan, Khadija AU - Balazs, Alejandro B. AU - Gosnell, Bernadett I. AU - Hanekom, Willem AU - Moosa, Mahomed-Yunus S. AU - NGS-SA AU - COMMIT-KZN Team AU - Lessells, Richard J. AU - de Oliveira, Tulio AU - Sigal, Alex TI - Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma AID - 10.1101/2021.01.26.21250224 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.26.21250224 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.26.21250224.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.26.21250224.full AB - New SARS-CoV-2 variants with mutations in the spike glycoprotein have arisen independently at multiple locations and may have functional significance. The combination of mutations in the 501Y.V2 variant first detected in South Africa include the N501Y, K417N, and E484K mutations in the receptor binding domain (RBD) as well as mutations in the N-terminal domain (NTD). Here we address whether the 501Y.V2 variant could escape the neutralizing antibody response elicited by natural infection with earlier variants. We were the first to outgrow two variants of 501Y.V2 from South Africa, designated 501Y.V2.HV001 and 501Y.V2.HVdF002. We examined the neutralizing effect of convalescent plasma collected from six adults hospitalized with COVID-19 using a microneutralization assay with live (authentic) virus. Whole genome sequencing of the infecting virus of the plasma donors confirmed the absence of the spike mutations which characterize 501Y.V2. We infected with 501Y.V2.HV001 and 501Y.V2.HVdF002 and compared plasma neutralization to first wave virus which contained the D614G mutation but no RBD or NTD mutations. We observed that neutralization of the 501Y.V2 variants was strongly attenuated, with IC50 6 to 200-fold higher relative to first wave virus. The degree of attenuation varied between participants and included a knockout of neutralization activity. This observation indicates that 501Y.V2 may escape the neutralizing antibody response elicited by prior natural infection. It raises a concern of potential reduced protection against re-infection and by vaccines designed to target the spike protein of earlier SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Investment INV-018944 (AS) and by the South African Medical Research Council and the Department of Science and Innovation (TdO).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nasopharyngeal/oropharyngeal swab samples and plasma samples were obtained from six hospitalized adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective cohort study ap- proved by the Biomedical Research Ethics Committee (BREC) at the University of KwaZulu-Natal (reference BREC/00001275/2020). The 501Y.V2 variants were obtained from residual nasopharyngeal/oropharyngeal samples used for routine SARS-CoV-2 diagnostic testing by the National Health Laboratory Service, through our SARS-CoV-2 genomic surveillance program (BREC approval reference BREC/00001510/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data is available at GISAID.